Diagnosis and management of multiple myeloma: a review
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
[HTML][HTML] Drug-induced oxidative stress in cancer treatments: Angel or devil?
H Jiang, J Zuo, B Li, R Chen, K Luo, X **ang, S Lu… - Redox Biology, 2023 - Elsevier
Oxidative stress (OS), defined as redox imbalance in favor of oxidant burden, is one of the
most significant biological events in cancer progression. Cancer cells generally represent a …
most significant biological events in cancer progression. Cancer cells generally represent a …
[HTML][HTML] Ide-cel or standard regimens in relapsed and refractory multiple myeloma
Background Survival is poor among patients with triple-class–exposed relapsed and
refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen …
refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen …
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
SV Rajkumar - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and …
F Gay, P Musto, D Rota-Scalabrini, L Bertamini… - The Lancet …, 2021 - thelancet.com
Background Bortezomib-based induction followed by high-dose melphalan (200 mg/m 2)
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results …
Background Lenalidomide and bortezomib frontline exposure has raised a growing need for
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …
novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in …
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation (HFA), the E …
Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …
of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position …
[HTML][HTML] Multiple myeloma current treatment algorithms
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …
practice recommendations for the treatment of relapsed and refractory multiple myeloma …